Spark Newswire Spark Newswire
  • Newswire
  • News
    • Guidance
    • Dividends
    • M&A
    • Buybacks
    • Legal
    • Interviews
    • Management
    • Offerings
    • IPOs
    • Insider Trades
    • Biotech/FDA
    • Tech
  • Markets
    • After Hours
    • Movers
    • ETFs
    • Forex
    • Commodities
    • Options
    • Binary Options
    • Bonds
    • Futures
    • Global Economics
    • Reviews
    • Small-Cap
    • Cryptocurrency
    • Penny Stocks
  • Analysts
    • Analyst Color
    • Analyst Ratings
    • Upgrades
    • Downgrades
  • Earnings
    • Earnings
  • Support & Feedback
  • Registration Options
  • Log In
News by Category
  • After-Hours Center
  • Analyst Color
  • Analyst Ratings
  • Asia
  • Asset Sales
  • Binary Options
  • Biotech
  • Bonds
  • Broad U.S. Equity ETFs
  • Buybacks
  • Cannabis
  • Commodities
  • Contracts
  • Crowdsourcing
  • Cryptocurrency
  • Currency ETFs
  • Dividends
  • Downgrades
  • Earnings
  • Earnings Beats
  • Earnings Misses
  • Econ #s
  • Economics
  • Education
  • Emerging Market ETFs
  • Emerging Markets
  • Entertainment
  • Entrepreneurship
  • Equities
  • ESG
  • ETFs
  • Eurozone
  • Events
  • Exclusives
  • FDA
  • Federal Reserve
  • Financial Advisors
  • Financing
  • Fintech
  • Forex
  • Futures
  • Gaming
  • General
  • Global
  • Government
  • Guidance
  • Health Care
  • Hedge Funds
  • Hot
  • Initiation
  • Insider Trades
  • Insurance
  • Interview
  • Intraday Update
  • IPOs
  • Large Cap
  • Latin America
  • Legal
  • Long Ideas
  • M&A
  • Macro Economic Events
  • Macro Notification
  • Management
  • Market Summary
  • Market-Moving Exclusives
  • Markets
  • Media
  • Mid Cap
  • Mining
  • Movers
  • Movers & Shakers
  • Mutual Funds
  • New ETFs
  • News
  • Offerings
  • Opinion
  • Options
  • Penny Stocks
  • Personal Finance
  • Politics
  • Pre-Market Outlook
  • Press Releases
  • Previews
  • Price Target
  • Psychedelics
  • Psychology
  • Real Estate
  • Regulations
  • REIT
  • Reiteration
  • Restaurants
  • Retail Sales
  • Reviews
  • Rumors
  • SEC
  • Sector ETFs
  • Short Ideas
  • Short Sellers
  • Signals
  • Small Business
  • Small Cap
  • Small Cap Analysis
  • Small-Cap
  • Social Media
  • SPACE
  • Specialty ETFs
  • Sports
  • Sports Betting
  • Startups
  • Stock Split
  • Success Stories
  • Tech
  • Technicals
  • Termination
  • Top Stories
  • Topics
  • Trading Ideas
  • Travel
  • Treasuries
  • Uncategorized
  • Upgrades
Spark Newswire Spark Newswire
Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.
  • Newswire
  • News
    • Guidance
    • Dividends
    • M&A
    • Buybacks
    • Legal
    • Interviews
    • Management
    • Offerings
    • IPOs
    • Insider Trades
    • Biotech/FDA
    • Tech
  • Markets
    • After Hours
    • Movers
    • ETFs
    • Forex
    • Commodities
    • Options
    • Binary Options
    • Bonds
    • Futures
    • Global Economics
    • Reviews
    • Small-Cap
    • Cryptocurrency
    • Penny Stocks
  • Analysts
    • Analyst Color
    • Analyst Ratings
    • Upgrades
    • Downgrades
  • Earnings
    • Earnings
  • Support & Feedback
  • Registration Options
  • Log In
Spark Newswire Spark Newswire
Filter By Ticker
Search By Date To
Today | Yesterday | This week
Browsing Category

Analyst Ratings

Analyst Ratings

Group By Ticker
Sort By
Newest | Oldest
Read More
1 minute read
  • Analyst Ratings

What 7 Analyst Ratings Have To Say About AbbVie

By Benzinga Insights
July 8, 8:41 AM
Over the past 3 months, 7 analysts have published their opinion on AbbVie (NYSE:ABBV) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.

ABBV

Read More
1 minute read
  • Analyst Ratings

Expert Ratings for Omnicom Group

By Benzinga Insights
July 8, 8:41 AM
Analysts have provided the following ratings for Omnicom Group (NYSE:OMC) within the last quarter:

OMC

Read More
2 minute read
  • Analyst Ratings

8 Analysts Have This to Say About 3M

By Benzinga Insights
July 8, 8:41 AM
Analysts have provided the following ratings for 3M (NYSE:MMM) within the last quarter:

MMM

Read More
1 minute read
  • Analyst Ratings

Where Agilent Technologies Stands With Analysts

By Benzinga Insights
July 8, 8:40 AM
Analysts have provided the following ratings for Agilent Technologies (NYSE:A) within the last quarter:

A

Read More
1 minute read
  • Analyst Ratings
  • News
  • Price Target

Citigroup Maintains Neutral on SeaWorld Entertainment, Lowers Price Target to $52

By Benzinga Newsdesk
July 8, 8:38 AM
Citigroup analyst James Hardiman maintains SeaWorld Entertainment (NYSE:SEAS) with a Neutral and lowers the price target from $62 to $52.

SEAS

Read More
1 minute read
  • Analyst Ratings
  • News
  • Price Target

Citigroup Maintains Buy on Cedar Fair, Lowers Price Target to $55

By Benzinga Newsdesk
July 8, 8:36 AM
Citigroup analyst James Hardiman maintains Cedar Fair (NYSE:FUN) with a Buy and lowers the price target from $67 to $55.

FUN

Read More
1 minute read
  • Analyst Ratings
  • News
  • Price Target

Raymond James Maintains Strong Buy on National Retail Props, Raises Price Target to $55

By Benzinga Newsdesk
July 8, 8:32 AM
Raymond James analyst RJ Milligan maintains National Retail Props (NYSE:NNN) with a Strong Buy and raises the price target from $50 to $55.

NNN

Read More
1 minute read
  • Analyst Ratings
  • News
  • Price Target

Raymond James Maintains Strong Buy on Gaming and Leisure Props, Raises Price Target to $56

By Benzinga Newsdesk
July 8, 8:30 AM
Raymond James analyst RJ Milligan maintains Gaming and Leisure Props (NASDAQ:GLPI) with a Strong Buy and raises the price target from $54 to $56.

GLPI

Read More
1 minute read
  • Analyst Ratings
  • News
  • Price Target

Truist Securities Maintains Buy on Arcus Biosciences, Lowers Price Target to $50

By Benzinga Newsdesk
July 8, 8:28 AM
Truist Securities analyst Robyn Karnauskas maintains Arcus Biosciences (NYSE:RCUS) with a Buy and lowers the price target from $77 to $50.

RCUS

Read More
1 minute read
  • Analyst Ratings
  • News
  • Price Target

Barclays Maintains Overweight on Parker Hannifin, Lowers Price Target to $329

By Benzinga Newsdesk
July 8, 8:23 AM
Barclays analyst Julian Mitchell maintains Parker Hannifin (NYSE:PH) with a Overweight and lowers the price target from $335 to $329.

PH

Posts pagination

Previous 1 … 4,366 4,367 4,368 … 4,420 Next
Free Newsletter subscribe

Stock Market Ideas & Analysis

Stay up-to-date with the same information professionals use.
Spark Newswire Spark Newswire
  • Newswire
  • Registration
  • Log In
  • Settings
  • Privacy Policy
  • Terms of Service
© 2021 Spark Newswire
All Rights Reserved.

All news is property of their respective owners. Terms of Service